Diabetes Metab J > Volume 45(6); 2021 > Article |
|
AUTHOR CONTRIBUTIONS
Conception or design: F.M.P., B.M.S., D.C.
Acquisition, analysis, or interpretation of data: F.M.P., C.D., G.C.K.D., L.H.C., D.C.
Drafting the work or revising: F.M.P., C.D., G.C.K.D., L.H.C., B.M.S., D.C.
Final approval of the manuscript: F.M.P., C.D., G.C.K.D., L.H.C., B.M.S., D.C.
FUNDING
The study was partially funded by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) and Fundo de Incentivo à Pesquisa e Eventos at Hospital de Clínicas de Porto Alegre (FIPE-HCPA) (grant number: 2018-0051).
Characteristic | Control group (n=518) | T1DM group (n=478) | P valuea |
---|---|---|---|
Age, yr | 39.1±10.0 | 38.3±12.6 | 0.296 |
Male sex, % | 59.1 | 51.5 | 0.019 |
T1DM duration, yr | - | 20.2±9.1 | - |
Ethnicity (non-White), % | 11.8 | 9.3 | 0.233 |
HbA1c, % (mmol/mol) | 5.3±0.3 (34±0.39) | 8.7±2.0 (72±10) | <0.0001 |
High-risk HLA DR/DQ genotypes, %b | 17.5 | 58.0 | <0.0001 |
BMI, kg/m2 | 27.1±4.5 | 24.4±3.7 | <0.0001 |
Hypertension, % | - | 46.4 | - |
Age at T1DM diagnosis, yr | - | 17.4±9.7 | - |
Diabetic kidney disease, % | - | 40.4 | - |
Diabetic retinopathy, % | - | 59.8 | - |
Variable | Control group (n=518) | T1DM group (n=478) | P valuea | Adjusted OR (95% CI)/P valueb |
---|---|---|---|---|
Genotypes | ||||
C/C | 282 (54.4) | 287 (60.0) | 0.001 | 1 |
C/A | 165 (31.9) | 161 (33.7) | 0.921 (0.660-1.285)/0.627 | |
A/A | 71 (13.7) | 30 (6.3) | 0.467 (0.275-0.794)/0.005 | |
Alleles | ||||
C | 0.704 | 0.769 | 0.001 | - |
A | 0.296 | 0.231 | ||
Recessive model | ||||
C/C+C/A | 447 (86.3) | 448 (93.7) | <0.0001 | 1 |
A/A | 71 (13.7) | 30 (6.3) | 0.482 (0.288-0.806)/0.005 | |
Additive model | ||||
C/C | 282 (79.9) | 287 (90.5) | <0.0001 | 1 |
A/A | 71 (20.1) | 30 (9.5) | 0.470 (0.278-0.794)/0.005 | |
Dominant model | ||||
C/C | 282 (54.4) | 287 (60.0) | 0.074 | 1 |
C/A+A/A | 236 (45.6) | 191 (40.0) | 0.782 (0.575-1.063)/0.116 |
Variable | Control group (n=456) | T1DM group (n=431) | P valuea | Adjusted OR (95% CI)/P valueb |
---|---|---|---|---|
White subjects | ||||
Genotypes | ||||
C/C | 240 (52.6) | 252 (58.5) | <0.0001 | 1 |
C/A | 147 (32.2) | 150 (34.8) | 0.839 (0.585-1.203)/0.339 | |
A/A | 69 (15.1) | 29 (6.7) | 0.485 (0.276-0.851)/0.012 | |
Alleles | ||||
C | 0.690 | 0.760 | <0.001 | - |
A | 0.310 | 0.240 | ||
Recessive model | ||||
C/C+C/A | 387 (84.9) | 402 (93.3) | <0.0001 | 1 |
A/A | 69 (15.1) | 29 (6.7) | 0.518 (0.301-0.894)/0.018 | |
Additive model | ||||
C/C | 240 (77.7) | 252 (89.7) | <0.0001 | 1 |
A/A | 69 (22.3) | 29 (10.3) | 0.488 (0.281-0.846)/0.011 | |
Dominant model | ||||
C/C | 240 (52.6) | 252 (58.5) | 0.093 | 1 |
C/A+A/A | 216 (47.4) | 179 (41.5) | 0.734 (0.526-1.023)/0.068 | |
Non-white subjects | 61 | 44 | ||
Genotypes | ||||
C/C | 41 (67.2) | 32 (72.7) | 0.823 | 1 |
C/A | 18 (29.5) | 11 (25.0) | 1.234 (0.389-3.910)/0.721 | |
A/A | 2 (3.3) | 1 (2.3) | 0.816 (0.056-11.957)/0.882 | |
Alleles | ||||
C | 0.820 | 0.850 | 0.661 | - |
A | 0.180 | 0.150 | ||
Dominant model | ||||
C/C | 41 (67.2) | 32 (72.7) | 0.696 | 1 |
C/A+A/A | 20 (32.8) | 12 (27.3) | 1.164 (0.393-3.451)/0.784 |
Characteristic | C/C+C/A (n=448) | A/A (n=30) | P valuea |
---|---|---|---|
Age, yr | 38.4±12.7 | 37.6±11.2 | 0.768 |
Age at diagnosis, yr | 17.3±9.8 | 18.5±9.9 | 0.557 |
T1DM duration, yr | 20.1±8.8 | 20.8±6.4 | 0.701 |
Male sex, % | 51.4 | 53.3 | 0.983 |
Ethnicity (non-white), % | 9.7 | 3.3 | 0.405 |
HbA1c, % (mmol/mol) | 8.7±2.0 (72±10) | 8.6±2.2 (70±12.5) | 0.772 |
T1DM high-risk HLA DR/DQ genotypes, % | 57.8 | 59.3 | >0.999 |
BMI, kg/m2 | 24.4±3.7 | 24.6±3.6 | 0.843 |
Hypertension, % | 46.1 | 50.0 | 0.876 |
Diabetic retinopathy, % | 60.2 | 53.6 | 0.623 |
Diabetic kidney disease, % | 39.2 | 56.5 | 0.254 |
Felipe Mateus Pellenz
https://orcid.org/0000-0002-7829-9407
Daisy Crispim
https://orcid.org/0000-0001-5095-9269
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
https://doi.org/10.13039/501100002322
Conselho Nacional de Desenvolvimento Científico e Tecnológico
https://doi.org/10.13039/501100003593
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
https://doi.org/10.13039/501100004263
Fundo de Incentivo à Pesquisa e Eventos at Hospital de Clínicas de Porto Alegre
2018-0051
Mitochondria DNA Polymorphism and Type 2 Diabetes Mellitus.2009 October;33(5)
Hemichorea Associated with Type II Diabetes Mellitus.2003 August;27(4)